Phase 2 Trial Tests High-Induction Risankizumab in Plaque Psoriasis
A randomized phase 2 trial in Nature tests high-induction dosing of risankizumab in moderate-to-severe plaque psoriasis, probing whether front-loaded dosing speeds clearance.
Topic
Phase 2 Trial
Topic
Phase 2 Trial
Enpatoran Phase 2 Trial Reports Symptom Improvement in Cutaneous Lupus
An oral TLR7/8 inhibitor met its Phase 2 primary endpoint in cutaneous lupus erythematosus, per a Dermatology Advisor report, tho…
Tulisokibart Hits HiSCR50 Endpoint in Phase 2b Hidradenitis Suppurativa Trial
High-dose tulisokibart reached HiSCR50 in 72% of HS patients at week 16 vs 35% on placebo in Merck's phase 2b MK-7240-012 trial,…
Pfizer's Tilrekimig Posts Phase 2 Skin Clearance Signal in AD
Pfizer's investigational IL-17 inhibitor tilrekimig produced a significant skin clearance signal in a Phase 2 atopic dermatitis t…
Pfizer's Trispecific Antibody Tilrekimig Hits EASI-75 in Phase 2 AD
Tilrekimig, a first-in-class trispecific antibody targeting IL-4, IL-13 and TSLP, delivered EASI-75 rates up to 62.5% at Week 16…
Daxdilimab Cuts Disease Activity in Moderate-to-Severe Discoid Lupus
Phase 2 data show daxdilimab reduced disease activity in moderate-to-severe discoid lupus, a cutaneous lupus subtype with few tar…
Pfizer Reports Tilrekimig Phase 2 Atopic Dermatitis Results
Pfizer has disclosed Phase 2 atopic dermatitis results for tilrekimig, its mid-stage candidate; detailed efficacy and safety data…
Daxdilimab Improves Disease Activity in Refractory Discoid Lupus
A Phase 2 trial found daxdilimab improved disease activity in patients with treatment-refractory discoid lupus erythematosus, a h…